Protein therapeutics - Lessons learned and a view of the future

Expert Opinion on Biological Therapy

Volumn 6, Issue 1, 2006, Pages 1-7

  Johnson Léger, Caroline ^b   Power, Christine A ^b   Shomade, Greyce ^b   Shaw, Jeffrey P ^b   Proudfoot, Amanda E I ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^b NONE

Author keywords

Biologics; Immunotherapy; Protein therapeutics

Indexed keywords

AGALSIDASE BETA; AUTOANTIBODY; BETA INTERFERON; BINDING PROTEIN; CELL SURFACE RECEPTOR; CORTICOSTEROID; CYTOKINE; CYTOKINE RECEPTOR; DEATH RECEPTOR; EPTIFIBATIDE; ETANERCEPT; FC RECEPTOR; FOLLITROPIN; HIRUDIN; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; ION CHANNEL; NONSTEROID ANTIINFLAMMATORY AGENT; OKT 3; PIG INSULIN; PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; THROMBIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ASTHMA; ATHEROSCLEROTIC PLAQUE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST; DIABETES MELLITUS; DRUG EFFICACY; DRUG FORMULATION; FABRY DISEASE; FLUID RETENTION; GLAUCOMA; HEPATITIS C; HUMAN; HUMAN GENOME; HYPERTENSION; IMMUNOGENICITY; IMMUNOTHERAPY; INFERTILITY; INFLAMMATION; MULTIPLE SCLEROSIS; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PURE RED CELL ANEMIA; REIMBURSEMENT; REVIEW; SKIN ATROPHY; THROMBOSIS; ULCER;

ANIMALS; ANTIBODIES; BIOPHARMACEUTICS; GENOME, HUMAN; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NEOPLASMS; PEPTIDES; PROTEIN ENGINEERING; PROTEINS; RECOMBINANT PROTEINS;

HEPATITIS C VIRUS; SUS SCROFA;

EID: 30044449750     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.1.1     Document Type: Review

References (37)

1. CLARKE JT, IWANOCHKO RM: Enzyme replacement therapy of Fabry disease. Mol. Neurobiol. (2005) 32:43-50.
2. LABRIOLA-TOMPKINS E, CHANDRAN C, KAFFKA KL et al.: Identification of the discontinuous binding site in human interleukin 1 beta for the Type I interleukin 1 receptor. Proc. Natl. Acad. Sci. USA (1991) 88:11182-11186.
3. CARTER DB, DEIBEL MR JR, DUNN CJ et al.: Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature (1990) 344:633-638.
4. GRANOWITZ EV, CLARK BD, MANCILLA J, DINARELLO CA: Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the Type II interleukin-1 receptor. J. Biol. Chem. (1991) 266:14147-14150.
5. NOVICK D, KIM SH, FANTUZZI G, REZNIKOV LL, DINARELLO CA, RUBINSTEIN M: Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity (1999) 10:127-136.
6. NOVICK D, ENGELMANN H, WALLACH D, LEITNER O, REVEL M, RUBINSTEIN M: Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J. Chromatogr. (1990) 510:331-337.
7. KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-497.
8. HWANG WY, FOOTE J: Immunogenicity of engineered antibodies. Methods (2005) 36:3-10.
9. CHOWDHURY PS, WU H: Tailor-made antibody therapeutics. Methods (2005) 36:11-24. A recent review that discusses the evolution of antibodies from murine to fully human, and how antibody engineering technologies may be employed to generate antibodies with defined specificity, affinity and effector functions.
10. STOCKS MR: Intrabodies: production and promise. Drug Discov. Today (2004) 9:960-966.
11. HENG BC, KEMENY DM, LIU H, CAO T: Potential applications of intracellular antibodies (intrabodies) in stem cell therapeutics. J. Cell Mol. Med. (2005) 9:191-195.
12. LUCAS A, MCFADDEN G: Secreted immunomodulatory viral proteins as novel biotherapeutics. J. Immunol. (2004) 173:4765-4774. This article cites the current state of non-human protein therapeutics.
13. ALCAMI A: Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. (2003) 3:36-50. Excellent review of virally encoded immunomodulatory proteins.
14. ROLLINS BJ: Chemokines. Blood (1997) 90:909-928.
15. FOXMAN EF, CAMPBELL JJ, BUTCHER EC: Multistep navigation and the combinatorial control of leukocyte chemotaxis. J. Cell Biol. (1997) 139:1349.
16. LUCAS A, LIU L, MACEN J et al.: Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation (1996) 94:2890-2900.
17. LIU L, DAI E, MILLER L et al.: Viral chemokine-binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. Transplantation (2004) 77:1652-1660.
18. PAESEN GC, ADAMS PL, HARLOS K, NUTTALL PA, STUART DI: Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. Mol. Cell (1999) 3:661-671.
19. HAJNICKA V, VANCOVA I, KOCAKOVA P et al.: Manipulation of host cytokine network by ticks: a potential gateway for pathogen transmission. Parasitology (2005) 130:333-342.
20. GREINACHER A, EICHLER P, ALBRECHT D, STROBEL U, POTZSCH B, ERIKSSON BI: Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood (2003) 101:2617-2619.
21. SCHELLEKENS H: Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. (2002) 1:457-462. A very interesting review that discusses the factors that influence immunogenicity.
22. PORTER S: Human immune response to recombinant human proteins. J. Pharm. Sci. (2001) 90:1-11.
23. BICHLER J, GEMMERLI R, FRITZ H: Studies for revealing a possible sensitization to hirudin after repeated intravenous injections in baboons. Thromb. Res. (1991) 61:39-51.
24. BUGELSKI PJ, TREACY G: Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Ther. (2004) 6:10-16. An excellent article that reviews the value and limitation of testing for immunogenicity in animal models.
25. BUSSIERE JL: Animal models as indicators of immunogenicity of therapeutic proteins in humans. Dev. Biol. (Basel) (2003) 112:135-139.
26. ZEUZEM S, FEINMAN SV, RASENACK J et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. (2000) 343:1666-1672.
27. PRESTA LG, SHIELDS RL, NAMENUK AK, HONG K, MENG YG: Engineering therapeutic antibodies for improved function. Biochem. Soc. Trans. (2002) 30:487-490.
28. GRIEBEN JG, DEVEREUX S, THOMAS NS et al.: Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet (1990) 335:434-437.
29. CASADEVALL N, NATAF J, VIRON B et al.: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. (2002) 346:469-475. An important study documenting the crossreactivity of antidrug antibodies with an endogenous protein thereby leading to a serious life-threatening condition. This was perhaps the first case study to bring the potential risks of immunogenicity of biologies to the forefront.
30. MATZINGER P: An innate sense of danger. Semin. Immunol. (1998) 10:399-415.
31. KAISHO T, AKIRA S: Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta (2002) 1589:1-13.
32. AKIRA S, HEMMI H: Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. (2003) 85:85-95.
33. DRESSER DW: Specific inhibition of antibody production. I. Protein-over loading paralysis. Immunology (1962) 5:161-168.
34. GAMBLE CN: The role of soluble aggregates in the primary immune response of mice to human gamma globulin. Int. Arch. Allergy Appl. Immunol. (1966) 30:446-455.
35. CHIRINO AJ, ARY ML, MARSHALL SA: Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today (2004) 9:82-90. A very comprehensive review that covers the topic of immunogenicity in detail, including the way in which antidrug antibodies are produced, how they are detected in patients, models for preclinical screening and some ways in which immunogenicity may be reduced.
36. WINSOR-HINES D, MERRILL C, O'MAHONY M et al.: Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J. Immunol. (2004) 173:4715-4723.
37. RYDEL TJ, RAVICHANDRAN KG, TULINSKY A et al.: The structure of a complex of recombinant hirudin and human alpha-thrombin. Science (1990) 249:277-280.